Caveolin-1 is required for the upregulation of fatty acid synthase (FASN), a tumor promoter, during prostate cancer progression.

Abstract:

:Prostate cancer is the second leading cause of cancer-related deaths in men. Fatty acid synthase (FASN) is normally upregulated during human prostate cancer onset and metastatic progression and its expression positively correlates with the development of advanced metastatic disease. However, it remains unknown what molecular factor(s) control FASN expression. It has been hypothesized that FASN functions as a tumor promoter during prostate cancer progression in humans. Consistently, an established mouse of model of prostate cancer, termed TRAMP mice, also shows the progressive upregulation of FASN levels during prostate cancer development. Here, we examine the role of caveolin-1 (Cav-1) in regulating FASN expression during prostate cancer progression. For this purpose, we crossed Cav-1-/- null mice with TRAMP mice to generate TRAMP/Cav-1+/+ and TRAMP/Cav-1-/- mice. Then, we assessed the expression of FASN in Cav-1+/+ and Cav-1-/- prostate tumors by immuno-histochemistry and Western blot analysis. Interestingly, our results indicate that FASN fails to be upregulated in Cav-1-/- tumors. Importantly, the tumors examined were the same morphological grade, but Cav-1-/- tumors were dramatically smaller and did not metastasize efficiently. We conclude that Cav-1 expression is normally required for the upregulation of FASN during prostate cancer progression. These results also mechanistically explain why TRAMP/Cav-1-/- mice are dramatically resistant to the development of prostate tumors and lung metastases, as they lack the expression of the FASN tumor promoter. Thus, TRAMP/Cav-1-/- mice will provide a novel model system to elucidate the role of FASN in prostate tumor progression. In addition, our results provide the first molecular genetic evidence that Cav-1 functions upstream of FASN during prostate cancer progression.

journal_name

Cancer Biol Ther

journal_title

Cancer biology & therapy

authors

Di Vizio D,Sotgia F,Williams TM,Hassan GS,Capozza F,Frank PG,Pestell RG,Loda M,Freeman MR,Lisanti MP

doi

10.4161/cbt.6.8.4447

subject

Has Abstract

pub_date

2007-08-01 00:00:00

pages

1263-8

issue

8

eissn

1538-4047

issn

1555-8576

pii

4447

journal_volume

6

pub_type

杂志文章
  • Hes1: a key role in stemness, metastasis and multidrug resistance.

    abstract::Hes1 is one mammalian counterpart of the Hairy and Enhancer of split proteins that play a critical role in many physiological processes including cellular differentiation, cell cycle arrest, apoptosis and self-renewal ability. Recent studies have shown that Hes1 functions in the maintenance of cancer stem cells (CSCs)...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章,评审

    doi:10.1080/15384047.2015.1016662

    authors: Liu ZH,Dai XM,Du B

    更新日期:2015-01-01 00:00:00

  • The preclinical evaluation of the dual mTORC1/2 inhibitor INK-128 as a potential anti-colorectal cancer agent.

    abstract::The colorectal cancer is the leading contributor of cancer-related mortality. Mammalian target of rapamycin (mTOR), existing in 2 complexes (mTORC1/2), is frequently dysregulated and constitutively activated in colorectal cancers. It represents an important drug target. Here we found that INK-128, the novel ATP-compet...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/15384047.2014.972274

    authors: Li C,Cui JF,Chen MB,Liu CY,Liu F,Zhang QD,Zou J,Lu PH

    更新日期:2015-01-01 00:00:00

  • All-trans-retinoic acid antagonizes the Hedgehog pathway by inducing patched.

    abstract::Male germ cell tumors (GCTs) are a model for a curable solid tumor. GCTs can differentiate into mature teratomas. Embryonal carcinomas (ECs) represent the stem cell compartment of GCTs and are the malignant counterpart to embryonic stem (ES) cells. GCTs and EC cells are useful to investigate differentiation therapy an...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.27821

    authors: Busch AM,Galimberti F,Nehls KE,Roengvoraphoj M,Sekula D,Li B,Guo Y,Direnzo J,Fiering SN,Spinella MJ,Robbins DJ,Memoli VA,Freemantle SJ,Dmitrovsky E

    更新日期:2014-04-01 00:00:00

  • Development of a biomimetic peptide derived from collagen IV with anti-angiogenic activity in breast cancer.

    abstract::Breast cancer is one of the most commonly diagnosed malignancies in women. Despite the remarkable success of mammography screening and use of adjuvant systemic therapy, it is estimated that approximately 200,000 new diagnoses will be made this year and 40,000 deaths will occur due to this disease (American Cancer Soci...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.12.9.17677

    authors: Rosca EV,Koskimaki JE,Pandey NB,Wolff AC,Popel AS

    更新日期:2011-11-01 00:00:00

  • β-Adrenergic receptors suppress Rap1B prenylation and promote the metastatic phenotype in breast cancer cells.

    abstract::A greater understanding of the molecular basis of breast cancer metastasis will lead to identification of novel therapeutic targets and better treatments. Rap1B is a small GTPase that suppresses the metastasis of breast cancer cells by increasing cell-cell adhesion. In breast cancer, a decrease in Rap1B prenylation an...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.1080/15384047.2015.1070988

    authors: Wilson JM,Lorimer E,Tyburski MD,Williams CL

    更新日期:2015-01-01 00:00:00

  • Enhanced antitumor effect of alectinib in combination with cyclin-dependent kinase 4/6 inhibitor against RET-fusion-positive non-small cell lung cancer cells.

    abstract::Rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) accounts for 1% of lung adenocarcinoma. Although small molecule agents with RET kinase inhibitory activity such as alectinib, vandetanib, and cabozantinib have been clinically evaluated in RET-fusion-positive NSCLC, an effective mo...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.1080/15384047.2020.1806643

    authors: Fujimura T,Furugaki K,Harada N,Yoshimura Y

    更新日期:2020-09-01 00:00:00

  • The biology of hormone refractory breast and prostate cancer: An NCI workshop report.

    abstract::The molecular regulation of growth and progression of hormone refractory breast and prostate cancers remains challenging. The Division of Cancer Biology, NCI organized a small "think tank" style workshop and invited scientists in relevant areas to assess the state of science on the biology of hormone refractory tumors...

    journal_title:Cancer biology & therapy

    pub_type:

    doi:10.4161/cbt.8.21.9918

    authors: Mohla S,Stearns V,Sathyamoorthy N,Rosenfeld MG,Nelson P

    更新日期:2009-11-01 00:00:00

  • Gemcitabine resistant pancreatic cancer cell lines acquire an invasive phenotype with collateral hypersensitivity to histone deacetylase inhibitors.

    abstract::Gemcitabine based treatment is currently a standard first line treatment for patients with advanced pancreatic cancer, however overall survival remains poor, and few options are available for patients that fail gemcitabine based therapy. To identify potential molecular targets in gemcitabine refractory pancreatic canc...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/15384047.2014.986967

    authors: Samulitis BK,Pond KW,Pond E,Cress AE,Patel H,Wisner L,Patel C,Dorr RT,Landowski TH

    更新日期:2015-01-01 00:00:00

  • Recurrent gliomas: comparison of computed tomography (CT)-guided 125I seed implantation therapy and traditional radiochemotherapy.

    abstract:BACKGROUND:Primary brain tumors have always been associated with high morbidity and mortality. Glioma is the most common type of malignant brain tumors,with a high probability of recurrence after surgical excision and with poor prognosis.The purpose of this study was to compare the therapeutic efficacy of computed tomo...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.20834

    authors: Hu X,Qiu H,Zhang L,Zhang W,Ma Y,Qiao Z,Chen D,Han J,Duan G,Zhang F

    更新日期:2012-08-01 00:00:00

  • Telomerase as a target for cancer immunotherapy.

    abstract::Telomerase is the ribonucleoprotein that enables cancer and stem cells to maintain their telomeres, resulting in unlimited proliferative potential. The catalytic component of telomerase in humans, hTERT, is upregulated in nearly 90% of all cancers, making it the most widely expressed marker of malignancy. With the exc...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章,评审

    doi:10.4161/cbt.2.2.255

    authors: Nguyen B,Elmore LW,Holt SE

    更新日期:2003-03-01 00:00:00

  • Myriocin, a serine palmitoyltransferase inhibitor, suppresses tumor growth in a murine melanoma model by inhibiting de novo sphingolipid synthesis.

    abstract::Advanced melanoma is the most virulent form of cancer and has a poor prognosis. In a previous study, myriocin, an inhibitor of serine palmitoyltransferase, was found to suppress melanoma cell proliferation by cell cycle arrest at the G 2/M phase through decreased sphingolipid levels and increased p53 and p21 (waf1/cip...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.13.2.18870

    authors: Lee YS,Choi KM,Lee S,Sin DM,Lim Y,Lee YM,Hong JT,Yun YP,Yoo HS

    更新日期:2012-01-15 00:00:00

  • Rational drug design: a GAGE derived peptide kills tumor cells.

    abstract::The current therapy of cancer fails to completely and exclusively target tumor cells. An ideal target for cancer therapy should be expressed exclusively in tumor cells and contribute to tumorigenesis. Targeting such a candidate gene would cause cell death only in tumor cells. A cancer testis antigen, GAGE, is consider...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.9.10.11588

    authors: Kular RK,Yehiely F,Deiss LP

    更新日期:2010-05-15 00:00:00

  • Phase II trial of single agent Val-boroPro (Talabostat) inhibiting Fibroblast Activation Protein in patients with metastatic colorectal cancer.

    abstract:PURPOSE:Fibroblast Activation Protein (FAP) is a tumor fibroblast protease that has been shown to potentiate colorectal cancer growth. The clinical impact of FAP inhibition was tested using Val-boroPro (Talabostat), the first clinical inhibitor of FAP enzymatic activity, in a phase II study of patients with metastatic ...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.6.11.4874

    authors: Narra K,Mullins SR,Lee HO,Strzemkowski-Brun B,Magalong K,Christiansen VJ,McKee PA,Egleston B,Cohen SJ,Weiner LM,Meropol NJ,Cheng JD

    更新日期:2007-11-01 00:00:00

  • Gefitinib-sensitizing mutation in esophageal carcinoma cell line Kyse450.

    abstract:PURPOSE:The sensitivity of lung cancer to gefitinib has been found to be associated with mutations at the tyrosine kinase domain of epidermal growth factor receptor (EGFR), yet similar observations are not available in other solid tumors. We recently identified mutations in the EGFR kinase domain in primary esophageal ...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.5.2.2318

    authors: Guo M,Liu S,Herman JG,Zhuang H,Lu F

    更新日期:2006-02-01 00:00:00

  • SUMO in cancer--wrestlers wanted.

    abstract::SUMO (small ubiquitin-related modifier) represents a class of ubiquitin-like proteins that is conjugated, like ubiquitin, by a set of enzymes to cellular regulatory proteins, including oncogenes and tumor suppressor genes, that play key roles in the control of cell growth, differentiation and apoptosis. SUMO conjugati...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章,评审

    doi:10.4161/cbt.74

    authors: Alarcon-Vargas D,Ronai Z

    更新日期:2002-05-01 00:00:00

  • Systemic and skin toxicity in Cercopithecus aethiops sabaeus monkeys treated during 26 weeks with a high intravenous dose of the anti- epidermal growth factor receptor monoclonal antibody Nimotuzumab.

    abstract::Nimotuzumab (h-R3) is a humanized anti-epidermal growth factor receptor monoclonal antibody (mAb) registered for treating head and neck tumours. The present study was designed to evaluate the systemic and skin toxicity of chronic intravenous administration of the h-R3 in a relevant species demonstrated by comparing th...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.6.9.4539

    authors: Arteaga ME,Ledón N,Casacó A,Pardo B,García M,Boleda M,Viña L,Orphee R,Hernández O,González C,Fuentes D,Rodríguez V,Charro L,Baro F,Macías A,Pérez A,Morales Y,Subirós N,González B,Ramos M,Rodriquez L,Ballester-La

    更新日期:2007-09-01 00:00:00

  • CXCL4 mediates tumor regrowth after chemotherapy by suppression of antitumor immunity.

    abstract::The recurrence of colorectal cancer after chemotherapy is the leading cause of its high mortality. We propose that elucidating the mechanisms of tumor regrowth after chemotherapy in tumor-bearing mice may provide new insights into tumor relapse in cancer patients. We firstly report the identification of a chemokine, C...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.1080/15384047.2015.1095404

    authors: Zhang Y,Gao J,Wang X,Deng S,Ye H,Guan W,Wu M,Zhu S,Yu Y,Han W

    更新日期:2015-01-01 00:00:00

  • Ototoxicity in patients with invasive ductal breast cancer who were treated with docetaxel: report of two cases.

    abstract::Docetaxel is an important anti-microtubule agent used to treat a variety of solid tumors, including breast cancer; notably, docetaxel-containing regimens improve outcomes for patients in metastatic, adjuvant, and neoadjuvant settings. However, the effectiveness of docetaxel in clinical practice can be compromised by s...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.1080/15384047.2020.1831370

    authors: Xuan L,Sun B,Meng X,Liu C,Cong Y,Wu S

    更新日期:2020-11-01 00:00:00

  • Upregulation of microRNA-129-5p inhibits cell invasion, migration and tumor angiogenesis by inhibiting ZIC2 via downregulation of the Hedgehog signaling pathway in cervical cancer.

    abstract::Recently, some studies have placed additional research focus on microRNAs (miRNAs) in a bid to discover novel therapeutic approaches for cervical cancer (CC), which is one of the most common female reproductive tract malignancies with high rates of morbidity and mortality. Hence, the aim of the present study was to ev...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.1080/15384047.2018.1491497

    authors: Wang YF,Yang HY,Shi XQ,Wang Y

    更新日期:2018-01-01 00:00:00

  • Polymorphism in the hypoxia-inducible factor 1alpha gene may confer susceptibility to androgen-independent prostate cancer.

    abstract::The hypoxia-inducible factor 1alpha (HIF-1alpha) plays a major role in cancer progression. The role of this transcription factor in prostate cancer development and its transition to a metastatic and androgen refractory state remains to be elucidated. Previous reports have identified the existence of single nucleotide ...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.4.11.2091

    authors: Chau CH,Permenter MG,Steinberg SM,Retter AS,Dahut WL,Price DK,Figg WD

    更新日期:2005-11-01 00:00:00

  • The efficacy of lorlatinib in a lung adenocarcinoma patient with a novel ALK G1202L mutation: a case report.

    abstract::Acquired mutations in anaplastic lymphoma kinase (ALK) gene have been implicated as the major resistance mechanism to ALK inhibitors; however, information on the treatment options after acquiring novel ALK secondary mutations is limited. Herein, we report the efficacy of lorlatinib upon the detection of a novel ALK G1...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.1080/15384047.2020.1836947

    authors: Meng Z,Li T,Wang P,Lizaso A,Huang D

    更新日期:2021-01-02 00:00:00

  • MEK1/2 inhibition promotes Taxotere lethality in mammary tumors in vivo.

    abstract::Taxol (paclitaxel) and Taxotere (docetaxel) are considered as two of the most important anti-cancer chemotherapy drugs. The cytotoxic action of these drugs has been linked to their ability to inhibit microtubule depolymerization, causing growth arrest and subsequent cell death. Studies by a number of laboratories have...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.5.10.3215

    authors: Yacoub A,Gilfor D,Hawkins W,Park MA,Hanna D,Hagan MP,Curiel DT,Fisher PB,Grant S,Dent P

    更新日期:2006-10-01 00:00:00

  • Polymorphisms of p53 and MDM2 genes are associated with severe toxicities in patients with non-small cell lung cancer.

    abstract::Adverse events in platinum-based chemotherapy for patients with advanced non-small cell lung cancer (NSCLC) are major challenges. In this study, we investigated the role of the p53 and MDM2 genes in predicting adverse events in NSCLC patients treated with platinum-based chemotherapy. Specifically, we examined the p53 ...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/15384047.2014.956599

    authors: Zheng D,Chen Y,Gao C,Wei Y,Cao G,Lu N,Hou Y,Jiang X,Wang J

    更新日期:2014-01-01 00:00:00

  • Furanonaphthoquinones cause apoptosis of cancer cells by inducing the production of reactive oxygen species by the mitochondrial voltage-dependent anion channel.

    abstract::The mitochondrial production of reactive oxygen species has been implicated in the anticancer activity of furanonaphthoquinone. However, the mechanism of the activation remains elusive. In the current study, we found that treatment of HeLa cells with 2-methyl-5(or -8)-hydroxy-furanonaphthoquinone (FNQ13) induces mitoc...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.5.11.3302

    authors: Simamura E,Hirai K,Shimada H,Koyama J,Niwa Y,Shimizu S

    更新日期:2006-11-01 00:00:00

  • Binding and inhibition of drug transport proteins by heparin: a potential drug transporter modulator capable of reducing multidrug resistance in human cancer cells.

    abstract::A major problem in cancer treatment is the development of resistance to chemotherapeutic agents, multidrug resistance (MDR), associated with increased activity of transmembrane drug transporter proteins which impair cytotoxic treatment by rapidly removing the drugs from the targeted cells. Previously, it has been show...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.27148

    authors: Chen Y,Scully M,Petralia G,Kakkar A

    更新日期:2014-01-01 00:00:00

  • Exposure to estrogen and ionizing radiation causes epigenetic dysregulation, activation of mitogen-activated protein kinase pathways, and genome instability in the mammary gland of ACI rats.

    abstract::The impact of environmental mutagens and carcinogens on the mammary gland has recently received a lot of attention. Among the most generally accepted carcinogenic agents identified as factors that may increase breast cancer incidence are ionizing radiation and elevated estrogen levels. However, the molecular mechanism...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.24599

    authors: Kutanzi K,Kovalchuk O

    更新日期:2013-07-01 00:00:00

  • Successful treatment using apatinib with or without docetaxel in heavily pretreated advanced non-squamous non-small cell lung cancer: A case report and literature review.

    abstract::Although targeted therapy directed toward driver mutations has produced a significant efficacy benefit for patients with non-small cell lung cancer (NSCLC), many patients do not possess mutations associated with the approved targeted drugs. Angiogenic agents play an important role in the therapeutic strategy for advan...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章,评审

    doi:10.1080/15384047.2017.1414757

    authors: Wu F,Zhang S,Gao G,Zhao J,Ren S,Zhou C

    更新日期:2018-03-04 00:00:00

  • Ras family signaling: therapeutic targeting.

    abstract::Mutationally activated and oncogenic versions of the ras genes were first identified in human tumors in 1982. This discovery prompted great interest in the development of anti-Ras strategies as novel, target-based approaches for cancer treatment. The three human ras genes represent the most frequently mutated oncogene...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章,评审

    doi:10.4161/cbt.306

    authors: Cox AD,Der CJ

    更新日期:2002-11-01 00:00:00

  • Therapeutic effect of arsenic trioxide (As2O3) on cervical cancer in vitro and in vivo through apoptosis induction.

    abstract::Arsenic trioxide (As2O3) induces apoptosis in certain types of cancer cells. But the detailed mechanisms of As2O3 efficacy are not completely known. Here we demonstrate that As2O3 has a therapeutic effect on cervical cancer in vitro and in vivo. We investigated the As2O3-induced apoptosis in various cervical cancer ce...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.6.4.3887

    authors: Yu J,Qian H,Li Y,Wang Y,Zhang X,Liang X,Fu M,Lin C

    更新日期:2007-04-01 00:00:00

  • KLF4 inhibition of lung cancer cell invasion by suppression of SPARC expression.

    abstract::Krüppel-Like Factor 4 (KLF4) functions as a tumor suppressor in some cancers, but its molecular mechanism is not clear. Our recent study also showed that the expression of KLF4 is dramatically reduced in primary lung cancer tissues. To investigate the possible role of KLF4 in lung cancer, we stably transfected KLF4 in...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.9.7.11106

    authors: Zhou Y,Hofstetter WL,He Y,Hu W,Pataer A,Wang L,Wang J,Zhou Y,Yu L,Fang B,Swisher SG

    更新日期:2010-04-01 00:00:00